Chelsea Therapeutics International Ltd. (
February 23, 2012 5:30 pm ET
Kathryn McNeil – Head-Investor & Media Relations
Simon Pedder – President & Chief Executive Officer
William D. Schwieterman – Chief Medical Officer
William B. White – Chief, Hypertension and Clinical Pharmacology Division & Professor, Department of Medicine, University of Connecticut Health Center
Robyn Karnauskas – Analyst, Deutsche Bank Securities, Inc.
Jonathan M. Eckard – Analyst, Leerink Swann LLC
Liana Moussatos – Analyst, Wedbush Securities, Inc.
Juan F. Sanchez – Analyst, Ladenburg Thalmann Securities
David S. Moskowitz – Analyst, ROTH Capital Partners LLC
Martin Shkreli – General Partner, MSMB Capital Management LLC
Good day, ladies and gentlemen, and welcome to Chelsea Therapeutics’ FDA Advisory Committee Update Conference Call. At this time, all participants are in a listen-only mode. Later, we’ll conduct a question-and-answer session, and instructions will be given at that time. (Operator Instructions) As a reminder, this conference call may be being recorded.
I would now like to hand the conference over to Ms. Kate McNeil. Ma’am, you may begin.
Thank you. Good afternoon, everyone, and thank you for joining us to discuss today’s meeting of the Cardiovascular and Renal Drugs Advisory Committee regarding NORTHERA NDA. Joining me from Chelsea is Dr. Simon Pedder, President and Chief Executive Officer; Dr. Bill Schwieterman, our Chief Medical Officer; Dr. Art Hewitt, our Chief Scientific Officer; and Joe Oliveto, our Chief Operating Officer.
We’re also joined today by Dr. Mark Stacy, Professor of Neurology at Duke Institute for Brain Sciences and Dr. William White, Chief of the Hypertension and Clinical Pharmacology Division at the University of Connecticut Health Center.